.jpg&w=256&q=75)
University of Sydney
Inspires curiosity and a thirst for knowledge.
This comment is not public.
This comment is not public.
This comment is not public.
This comment is not public.
This comment is not public.
Professor David Gracey, MBBS FRACP PhD FHEA, serves as a Clinical Professor in the Faculty of Medicine and Health at the University of Sydney, within the Central Clinical School. He is also a Senior Staff Specialist Renal and Renal Transplant Physician at Royal Prince Alfred Hospital, Sydney, where he contributes to the Statewide Renal Transplant Service. Gracey earned his MBBS and completed specialist training as a Fellow of the Royal Australasian College of Physicians (FRACP) in Internal Medicine and Nephrology. He obtained his PhD from the University of Sydney at the Centenary Institute, focusing on the immunological mechanisms of renal allograft rejection. Additionally, he is a Fellow of the Higher Education Academy (FHEA). His career includes roles as Associate Professor in the Discipline of Medicine at the University of Sydney and Senior Researcher at Royal Prince Alfred Hospital's Renal Transplant Unit since 2011.
Gracey's research specializations center on the interaction between the immune system and renal disease, particularly in renal transplantation, transplant immunology, and kidney disease among patients with chronic viral infections such as HIV. He has authored key clinical guidelines, including the KHA-CARI guideline on recipient assessment for transplantation (Nephrology, 2013) and a consensus statement on renal monitoring for Australian patients receiving tenofovir-based antiviral therapy for HIV/HBV infection (AIDS Research and Therapy, 2014). Prominent publications include "Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV" (AIDS Research and Therapy, 2020, 107 citations), "Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection" (Antiviral Therapy, 2013, 94 citations), "Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial" (The Lancet, 2023, 80 citations), and "Outcomes of Dialysis Patients Living With HIV in Australia and New Zealand" (2025). With over 850 citations on Google Scholar and ResearchGate, his work has advanced understanding of nephrology in immunocompromised populations. Gracey chairs the NSW Transplant Advisory Committee, influencing transplant policy and practice. As a Clinical Professor, he contributes to medical education and training at the University of Sydney.
Professional Email: david.gracey@sydney.edu.au